Acne vulgaris treated with isotretinoin in patients with inflammatory bowel disease, a single-center retrospective study

Arielle R. Nagler, MD^{1*}; Michelle Sikora, BS^{1,2*}; Kristen Lo Sicco, MD¹; Adam Faye, MD³; Jordan Axelrad, MD, MPH^{3*}; Avrom S. Caplan, **MD**^{1*}

¹The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY 10016, USA. ² New York Medical College, Valhalla, NY, 10595, USA. ³ Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology and Hepatology, NYU School of Medicine, New York, NY, USA *Both authors contributed equally as co-first or co-last

Background

- Oral isotretinoin stands as the primary treatment for severe acne vulgaris (AV).¹
- Both AV and isotretinoin have been associated with inflammatory bowel disease (IBD)^{2,3}
- Limited research exists on the impact of isotretinoin on preexisting IBD. ^{3–5}
- This study aims to explore the connection between isotretinoin use and IBD flares in patients with both IBD and AV.^{3–5}

Methods

- IRB-approved retrospective review of patients with IBD and AV conducted at NYU Langone Health (2008-2023).
- Inclusion criteria: ICD-10 codes for IBD and AV, documented isotretinoin use.
- An IBD flare was defined as a new corticosteroid requirement, advanced IBD therapy addition/escalation, or IBD-related hospitalization.
- Data collection included demographics, isotretinoin regimen, IBD characteristics, and disease activity.
- Patients acted as their own controls, comparing flares 2 years before and after isotretinoin exposure.
- Flare episodes were compared using Fisher's Exact Test.

	Resul		
No. (%)			
Cases (n = 10)	• Ton n		
8 (80)	UC, a		
2 (20)			
16.7 (5.9)	• INU as		
290(77)	found		
20.0 (7.7)			
	• ISOLIE		
8 (80)	highe		
2 (20)	comp		
	expos		
4 (40)	Слро		
6 (60)			
1520 (752 246 6)	Cono		
152.0(75.2, 240.0)	Conci		
	No. (%)Cases (n = 10) $8 (80)$ $2 (20)$ $16.7 (5.9)$ $28.0 (7.7)$ $8 (80)$ $2 (20)$ $4 (40)$ $6 (60)$ $152.0 (75.2, 246.6)$		

Table 2. IBD Flare Episodes in Relation to Isotretinoin Exposure

		Flare occurrence in relation to isotretinoin exposure		
Patient (n=10)	Total IBD Flare Episodes (n=13)	Before	During	After
1	7	2	3	2
2	-	-	-	-
3	-	-	-	-
4	1	-	-	1
5	-	-	-	-
6	3	1	2	-
7	2	2	-	-
8	_	-	-	-
9	-	_	-	-
10			-	-

lusion

References

- doi:10.1016/j.jaad.2023.01.014



patients underwent 10 isotretinoin (ISO) courses; 40% had and 60% had CD.

ssociation between ISO exposure and IBD flares was d (*p*=0.183).

etinoin flares during or after treatment did not have a er risk of needing advanced therapy or hospitalization pared to those with a history of flares before isotretinoin sure.

 No association was found between isotretinoin use and IBD. flares, indicating it may be a safe and effective treatment option.

• More research is needed to understand the connection between IBD and isotretinoin, especially with IBD prevalence rising.²

Limitations include a small sample size.

1. Layton A. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162-169. doi:10.4161/derm.1.3.9364

2. Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13. doi:10.3389/fphys.2012.00013

3. Wright S, Strunk A, Garg A. Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin. J Am Acad Dermatol. 2021;84(1):41-45. doi:10.1016/j.jaad.2020.07.042

4. Taylor MT, Margolis DJ, Kwatra SG, Barbieri JS. A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease. J Am Acad Dermatol. 2023;88(4):841-847.

5. Lopez CG, Kwak R, McCormack L, Zhou G, Charrow A. Impact of isotretinoin on inflammatory bowel disease flare in patients with preexisting inflammatory bowel disease diagnosis: A cross-sectional study. J Am Acad Dermatol. 2022;87(6):1399-1400.